Clinical Trial Update: The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial evaluating the safety and potential efficacy of donor-derived allogeneic gamma-delta T cells in patients with measurable residual disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Allogeneic γδT Cells

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: AML (Acute Myelogenous Leukemia), AML | EARLY_Phase 1 | Status: RECRUITING